Toei Shinyaku Granted U.S. Patent for Beta-Glucan Detection and Quantification Technology Developed Through King Agaricus KA21 Research
Posted on October 23 2026,
Toei Shinyaku Co., Ltd. has been granted a U.S. patent (US 12,736,534 B2, issued September 15, 2026) for a method and kit for detecting and quantifying beta-1,6-branched beta-1,3-glucan and beta-1,3-glucan. The technology was developed through joint research on King Agaricus KA21 (outdoor-cultivated Agaricus brasiliensis KA21) with the Department of Immunology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
With this patent, all three of our Japanese patents on beta-glucan measurement are now also registered in the United States.
Patent Details
- U.S. Patent No.: US 12,736,534 B2
- Issue date: September 15, 2026
- Title: Method for detecting and quantifying beta-1,6-branched beta-1,3-glucan or beta-1,3-glucan, and kit for detecting and quantifying the same
- Patent holder: Toei Shinyaku Co., Ltd.
- Inventors: Daisuke Yamanaka, Yoshiyuki Adachi
- Application: U.S. 17/910,526 (PCT/JP2021/032154; priority date September 7, 2020)
- Corresponding Japanese patent: JP 7632898 (registered February 10, 2025)
About the Technology
Beta-glucans are the main components of mushrooms such as Agaricus, and their properties differ depending on how they are linked and branched. This technology uses a split reporter protein to detect and quantify beta-1,6-branched beta-1,3-glucan and beta-1,3-glucan. When the target glucan is present in a sample, fusion proteins that bind to it reconstitute an active reporter protein, and the glucan is quantified by measuring that activity.
Potential applications include:
- Diagnostic kits for fungal infections (currently at the basic research stage)
- Measuring beta-glucan content and evaluating the quality of supplements, including King Agaricus KA21
- Research on how beta-glucans act in the body
Our Beta-Glucan Measurement Patents (Japan and U.S.)
- Beta-glucan-binding protein, beta-glucan detection kit, artificial DNA and bacterium: JP 6966756 (2021) / US 11,542,307 B2 (2023)
- Beta-1,6-glucanase mutant and method for measuring beta-1,6-glucan: JP 7052967 (2022) / US 11,479,803 B2 (2022)
- Method and kit for detecting and quantifying beta-1,6-branched beta-1,3-glucan or beta-1,3-glucan (this patent): JP 7632898 (2025) / US 12,736,534 B2 (2026)
About King Agaricus KA21
King Agaricus KA21 is grown from our exclusive KA21 strain, cultivated outdoors under natural sunlight in Brazil, the native home of Agaricus (Agaricus blazei / brasiliensis / subrufescens). Compared with indoor-grown Agaricus, it contains higher levels of vitamin D and other nutrients (Japan Food Research Laboratories), and its antioxidant activity has been reported to be more than five times higher (International Journal of Medicinal Mushrooms, 2019; 21(3): 31–43).
Press release (English): https://en.atpress.com/news/643244
